drugset
Drugs / Autologous tumor-infiltrating lymphocyte cells
last change Jul 2025 re-read 3 minutes ago

Autologous tumor-infiltrating lymphocyte cells

Cell therapy

Developed for
neoplasm
Investigated by
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Hervor Therapeutics · Jinling Hospital, China · Women's Hospital School Of Medicine Zhejiang University

Trials 1

today NCT06334783 · Ph 1
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06334783 May 2023 → Jan 2025 neoplasm Hervor Therapeutics Terminated No outcome recorded Stop: Business

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Autologous tumor-infiltrating lymphocyte cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT06334783 ↗
Modality Cell therapy “Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy” NCT06334783 ↗